Akirov Alfred 4
4 · Protalix BioTherapeutics, Inc. · Filed Mar 12, 2013
Insider Transaction Report
Form 4
Akirov Alfred
Director
Transactions
- Sale
Common Stock
2013-03-08$5.91/sh−2,500$14,775→ 5,060,411 total(indirect: By Corporation) - Sale
Common Stock
2013-03-11$5.75/sh−3,000$17,250→ 5,052,713 total(indirect: By Corporation) - Sale
Common Stock
2013-03-11$5.72/sh−10,000$57,200→ 5,042,713 total(indirect: By Corporation) - Sale
Common Stock
2013-03-08$5.82/sh−10,000$58,200→ 5,062,911 total(indirect: By Corporation) - Sale
Common Stock
2013-03-08$5.92/sh−2,500$14,800→ 5,057,911 total(indirect: By Corporation) - Sale
Common Stock
2013-03-11$5.79/sh−300$1,737→ 5,055,713 total(indirect: By Corporation) - Sale
Common Stock
2013-03-11$5.71/sh−5,000$28,550→ 5,037,711 total(indirect: By Corporation) - Sale
Common Stock
2013-03-08$5.95/sh−1,898$11,293→ 5,056,013 total(indirect: By Corporation)
Footnotes (1)
- [F1]All sales reported on this Form 4 were made by Alrov (Israel) Ltd.("Alrov Israel") and the column in Table 1 disclosing the amount of securities beneficially owned following the reported transactions includes 686,046 shares of our common stock held by Technorov Holdings (1993) Ltd. ("Technorov"). Alrov Israel owns 100% of Al-Rov Technologies Holdings LTD, the holder of 80% of Technorov. The reporting person is the Chairman of Alrov Israel and the Chief Executive Officer of Technorov, and has the power to control their respective investment decisions. Alrov Israel is an Israeli publicly-traded company that is listed on the Tel Aviv Stock Exchange. Mr. Akirov disclaims beneficial ownership of the securities of the Issuer held by Alrov Israel and Technorov, except to the extent of his proportional pecuniary interest therein.